Announcements Trials

Browse Landscape

Phase

Status

Completed 7 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 19 Lung Neoplasms 5 Small Cell Lung Carcinoma 4 Ovarian Neoplasms 4 Neoplasms 4 Colorectal Neoplasms 4 Uterine Cervical Neoplasms 3 Urinary Bladder Neoplasms 3 Squamous Cell Carcinoma of Head and Neck 3 Recurrence 3 Pancreatic Neoplasms 3 Neoplasm Metastasis 3 Multiple Myeloma 3 Lymphoma, Large B-Cell, Diffuse 3 Breast Neoplasms 3 Vulvar Neoplasms 2 Vaginal Neoplasms 2 Triple Negative Breast Neoplasms 2 Prostatic Neoplasms 2 Lymphoma, Non-Hodgkin 2 Head and Neck Neoplasms 2 Cholangiocarcinoma 2 Carcinoma, Transitional Cell 2 Carcinoma, Hepatocellular 2 Urothelial Cancer 1 Urinary Bladder Diseases 1 Thyroid Neoplasms 1 Thyroid Cancer, Papillary 1 Thrombocytosis 1 Testicular Neoplasms 1

Interventions

pembrolizumab 3 Carboplatin 3 Nivolumab 2 Injections 2 Docetaxel 2 Cisplatin 2 BMS-753493 2 zimberelimab 1 urelumab 1 tislelizumab 1 tesetaxel 1 spartalizumab 1 olaparib 1 liposomal doxorubicin 1 linifanib 1 lenvatinib 1 ixabepilone 1 durvalumab 1 avelumab 1 avdoralimab 1 adavosertib 1 TAS-119 1 Rifampin 1 N-(2-fluoro-4-((2-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)carbonylaminopyridin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide 1 Maximum Tolerated Dose 1 Linoleic Acids, Conjugated 1 Lapatinib 1 Itraconazole 1 Irinotecan 1 Ipilimumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Advanced Solid Tumors × durvalumab × Clear all

NCT03665129 2022-01-27

STELLAR-001

Innate Pharma

Phase 1 Terminated

Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡